Diabetes
From the Journals
COVID booster may transiently raise glucose levels in T1D
“Clinicians, pharmacists, and other health care providers may need to counsel people with T1D to be more vigilant with glucose testing and insulin...
Conference Coverage
SGLT2 inhibitors: No benefit or harm in hospitalized COVID-19
“I think the most important take-home message here is that the use of these medications appears to be safe even in really acutely ill hospitalized...
Conference Coverage
Heart attack deaths static in those with type 1 diabetes
“Clinicians have to be aware of the absence of the declined mortality trend in people with type 1 diabetes having a first-time myocardial...
Latest News
Diabetes patients satisfied with continuous glucose monitors
Overall, 90% agreed that most sensors were accurate, but just 79% and 78%, respectively, were satisfied with sensor performance on the first and...
Latest News
Night owls have higher risk of developing type 2 diabetes
Those with a preference for waking up later had a 72% higher risk for diabetes and were 54% more likely to have unhealthy lifestyle behaviors,...
PURLs
Should you treat prediabetes? It’s complicated
While treatment with metformin or lifestyle modification reduces risk for T2D in patients with prediabetes, neither intervention ultimately offers...
Clinical Inquiries
Is low-dose naltrexone effective in chronic pain management?
EVIDENCE-BASED ANSWER: YES. Low-dose naltrexone is as effective as amitriptyline in the treatment of painful diabetic neuropathy and has a...
Conference Coverage
Low-dose aspirin cuts type 2 diabetes risk in over-65s
“At this time, our findings are exploratory but ignite the debate of the important role that anti-inflammatory approaches may play in preventing...
From the Journals
Diabetes drug class appears to reduce recurrent gout flares
Previously associated with a lower incidence of gout, SGLT2 inhibitors for the first time also appear to reduce gout flare recurrence and excess...
Conference Coverage
Screening finds high rates of CVD in diabetes, COPD patients
The study tested a “very simple” symptom questionnaire as the initial screening phase, yet resulted in a CVD diagnostic rate that was two- to...
News from the FDA/CDC
FDA clears new capabilities for diabetes app BlueStar
The clearance enables the app-based platform to provide bolus insulin dose recommendations that are based on glucose and trend data from a...